FDA warns of cardiac risk with stress test agents

FDA warns of cardiac risk with stress test agents

(HealthDay)—The use of cardiac nuclear stress test agents comes with a rare but serious risk of heart attack and death, according to a warning sent by the U.S. Food and Drug Administration to health care professionals.

Lexiscan (regadenoson) and Adenoscan (adenosine), used in cardiac stress tests in patients who cannot exercise adequately, help identify coronary artery disease by dilating heart arteries and increasing blood flow. The risk stems from reduced blood flow to obstructed areas, which may result in potentially fatal .

The FDA has approved drug label changes for the two drugs to highlight these risks and update recommendations for their use. At this time, it is not clear if there is any difference in risk between Lexiscan and Adenoscan.

According to the agency, should "screen all candidates for their suitability to receive Lexiscan or Adenoscan. Avoid using these drugs in patients with signs or symptoms of unstable angina or cardiovascular instability, as these patients may be at greater risk for serious cardiovascular adverse reactions."

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Study: Removing clot helps limit stroke disability

6 hours ago

For the first time in several decades, a new treatment has been shown to limit the damage from a common type of stroke. Researchers in the Netherlands found that mechanically removing a clot in addition to using a clot-busting ...

Growing shortage of stroke specialists seen

12 hours ago

Although stroke is the No. 4 cause of death and a leading cause of disability in the United States, there's an increasing shortage of neurologists who specialize in stroke care.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.